PharmaShots | Incisive News in 3 Shots

Subscribe Now

Samsung Bioepis

Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria

Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobi...

May 31, 2023

Samsung Bioepis Reports P-III Trial Results of SB3 (biosimilar, trastuzumab) for HER2-Positive Breast Cancer

Samsung Bioepis Reports P-III Trial Results of SB3 (biosimilar, trastuzumab) for HER2-Positive Breast Cancer

May 8, 2023

Samsung Bioepis Presents 52 Weeks P-III Study Results of SB15, Proposed biosimilar to Eylea (aflibercept) for Neovascular Age-Related Macular Degeneration at ARVO 2023

Samsung Bioepis Presents 52 Weeks P-III Study Results of SB15, Proposed biosimilar to Eylea (aflibercept) for Neovascular Age-Rela...

April 25, 2023

Samsung Bioepis Reports P-III Study Results of SB11 (biosimilar, ranibizumab) for Neovascular Age-Related Macular Degeneration

Samsung Bioepis Reports P-III Study Results of SB11 (biosimilar, ranibizumab) for Neovascular Age-Related Macular Degeneration

April 22, 2023

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

Samsung Bioepis Reports P-I Study Results of SB17, a Proposed Biosimilar to Stelara

Samsung Bioepis Reports P-I Study Results of SB17, a Proposed Biosimilar to Stelara

March 17, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us